+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 56 Pages
  • June 2023
  • GlobalData
  • ID: 1292275
Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biotest AG (Biotest), a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East, and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary and Spain and Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.

Biotest AG Key Recent Developments

  • May 09, 2023: Biotest annual general meeting elects Raimon Grifols Roura to the supervisory board
  • Apr 20, 2023: Biotest opens 10th plasma collection centre in Germany
  • Feb 10, 2023: Biotest Supervisory Board appoints new Management Board member
  • Feb 09, 2023: Biotest significantly exceeds EBIT guidance 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Biotest AG - Key Facts
  • Biotest AG - Key Employees
  • Biotest AG - Key Employee Biographies
  • Biotest AG - Major Products and Services
  • Biotest AG - History
  • Biotest AG - Company Statement
  • Biotest AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Biotest AG - Business Description
  • Business Segment: Other Segments
  • Overview
  • Performance
  • Business Segment: Plasma & Services
  • Overview
  • Performance
  • Business Segment: Therapy
  • Overview
  • Performance
  • Geographical Segment: Central Europe
  • Performance
  • Geographical Segment: East and South Europe
  • Performance
  • Geographical Segment: Intercontinental
  • Performance
  • Geographical Segment: Middle East, Africa and France
  • Performance
  • R&D Overview
  • Biotest AG - Corporate Strategy
  • Biotest AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Biotest AG - Strengths
  • Biotest AG - Weaknesses
  • Biotest AG - Opportunities
  • Biotest AG - Threats
  • Biotest AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biotest AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Biotest AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2023: Biotest annual general meeting elects Raimon Grifols Roura to the supervisory board
  • Apr 20, 2023: Biotest opens 10th plasma collection centre in Germany
  • Feb 10, 2023: Biotest Supervisory Board appoints new Management Board member
  • Feb 09, 2023: Biotest significantly exceeds EBIT guidance 2022
  • Oct 13, 2022: Biotest opens 14th plasma collection centre in the Czech Republic
  • Aug 11, 2022: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 20
  • Aug 09, 2022: Biote Reports Second Quarter 2022 Financial Results
  • Jul 28, 2022: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR
  • May 05, 2022: Biotest announce annual general meeting and approves dividend distribution
  • May 05, 2022: Biotest records sales of 115 million euros in the first quarter of 2022
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Biotest AG, Key Facts
  • Biotest AG, Key Employees
  • Biotest AG, Key Employee Biographies
  • Biotest AG, Major Products and Services
  • Biotest AG, History
  • Biotest AG, Other Locations
  • Biotest AG, Subsidiaries
  • Biotest AG, Key Competitors
  • Biotest AG, Ratios based on current share price
  • Biotest AG, Annual Ratios
  • Biotest AG, Interim Ratios
  • Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biotest AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Biotest AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Biotest AG, Performance Chart (2018 - 2022)
  • Biotest AG, Ratio Charts
  • Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Stratec SE
  • Takeda Pharmaceutical Co Ltd
  • Viramed Biotech AG
  • Halozyme Therapeutics Inc
  • Medivir AB
  • Celltrion Inc
  • Takeda Pharmaceutical Co Ltd
  • Medivir AB
  • Celltrion Inc
  • Grifols SA
  • Halozyme Therapeutics Inc
  • Stratec SE
  • Viramed Biotech AG